Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study

Objective: We evaluated the efficacy, safety, and drug survival rate of tocilizumab in the elderly patients with rheumatoid arthritis (RA). Methods: This study was conducted in 108 RA patients who started tocilizumab between 2008 and 2018. The patients were divided into a young group (<65 years)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshinobu Nakao, Yu Funakubo Asanuma, Takuma Tsuzuki Wada, Mayumi Matsuda, Hiroaki Yazawa, Yoshihiro Yoshida, Akira Todoriki, Ayumi Shintani, Toshihide Mimura
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/40bf5bde4d984b6b9bd4dfa2440ba935
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40bf5bde4d984b6b9bd4dfa2440ba935
record_format	dspace
spelling	oai:doaj.org-article:40bf5bde4d984b6b9bd4dfa2440ba9352021-11-21T01:33:50ZEfficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study2058-739210.1177/20587392211045790https://doaj.org/article/40bf5bde4d984b6b9bd4dfa2440ba9352021-09-01T00:00:00Zhttps://doi.org/10.1177/20587392211045790https://doaj.org/toc/2058-7392Objective: We evaluated the efficacy, safety, and drug survival rate of tocilizumab in the elderly patients with rheumatoid arthritis (RA). Methods: This study was conducted in 108 RA patients who started tocilizumab between 2008 and 2018. The patients were divided into a young group (<65 years) and an elderly group (≥65 years). The efficacy, safety, and drug survival rate of tocilizumab were compared between the two groups. Results: At baseline, there were no significant differences between the elderly ( n = 45) and the young group ( n = 63) in RA duration, percentage of biologic-naïve, and RA disease activity. Health Assessment Questionnaire-Disability Index (HAQ-DI) was higher, renal function was worse, and frequency of using methotrexate was lower in the elderly group. Tocilizumab demonstrated similar efficacy in the elderly and the young group with Clinical Disease Activity Index and HAQ-DI. Compared with baseline, the frequency of steroid use was lower at one year after initiation of tocilizumab in both groups. There was no significant difference between the groups in the drug survival rate of tocilizumab for three years. Discontinuation rates of TCZ due to toxic adverse events were similar between the two groups. Conclusions: The efficacy, steroid-sparing effect, and safety of tocilizumab therapy, as well as the drug survival rate for three years, were not inferior in elderly RA compared to young RA patients.Yoshinobu NakaoYu Funakubo AsanumaTakuma Tsuzuki WadaMayumi MatsudaHiroaki YazawaYoshihiro YoshidaAkira TodorikiAyumi ShintaniToshihide MimuraSAGE PublishingarticleMedicineRENEuropean Journal of Inflammation, Vol 19 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Yoshinobu Nakao Yu Funakubo Asanuma Takuma Tsuzuki Wada Mayumi Matsuda Hiroaki Yazawa Yoshihiro Yoshida Akira Todoriki Ayumi Shintani Toshihide Mimura Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
description	Objective: We evaluated the efficacy, safety, and drug survival rate of tocilizumab in the elderly patients with rheumatoid arthritis (RA). Methods: This study was conducted in 108 RA patients who started tocilizumab between 2008 and 2018. The patients were divided into a young group (<65 years) and an elderly group (≥65 years). The efficacy, safety, and drug survival rate of tocilizumab were compared between the two groups. Results: At baseline, there were no significant differences between the elderly ( n = 45) and the young group ( n = 63) in RA duration, percentage of biologic-naïve, and RA disease activity. Health Assessment Questionnaire-Disability Index (HAQ-DI) was higher, renal function was worse, and frequency of using methotrexate was lower in the elderly group. Tocilizumab demonstrated similar efficacy in the elderly and the young group with Clinical Disease Activity Index and HAQ-DI. Compared with baseline, the frequency of steroid use was lower at one year after initiation of tocilizumab in both groups. There was no significant difference between the groups in the drug survival rate of tocilizumab for three years. Discontinuation rates of TCZ due to toxic adverse events were similar between the two groups. Conclusions: The efficacy, steroid-sparing effect, and safety of tocilizumab therapy, as well as the drug survival rate for three years, were not inferior in elderly RA compared to young RA patients.
format	article
author	Yoshinobu Nakao Yu Funakubo Asanuma Takuma Tsuzuki Wada Mayumi Matsuda Hiroaki Yazawa Yoshihiro Yoshida Akira Todoriki Ayumi Shintani Toshihide Mimura
author_facet	Yoshinobu Nakao Yu Funakubo Asanuma Takuma Tsuzuki Wada Mayumi Matsuda Hiroaki Yazawa Yoshihiro Yoshida Akira Todoriki Ayumi Shintani Toshihide Mimura
author_sort	Yoshinobu Nakao
title	Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
title_short	Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
title_full	Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
title_fullStr	Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
title_full_unstemmed	Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study
title_sort	efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: a real-world observational study
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/40bf5bde4d984b6b9bd4dfa2440ba935
work_keys_str_mv	AT yoshinobunakao efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT yufunakuboasanuma efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT takumatsuzukiwada efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT mayumimatsuda efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT hiroakiyazawa efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT yoshihiroyoshida efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT akiratodoriki efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT ayumishintani efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy AT toshihidemimura efficacysafetyandadherenceoftocilizumabtherapyinelderlypatientswithrheumatoidarthritisarealworldobservationalstudy
_version_	1718419359909543936

Efficacy, safety, and adherence of tocilizumab therapy in elderly patients with rheumatoid arthritis: A real-world observational study

Ejemplares similares